ARCHIVES

Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 7 | July 27, 2012

Download PDF Visit The Full Archive

Related Articles

DOD To Reimburse Care On Clinical Trials In Three-Year Deal

February 9, 1996

Russian-American Breast Cancer Meeting Canceled

April 14, 1995

GAO Study Claiming No Benefit Seen In Adjuvant Breast Cancer Treatment Flawed, NCI Responds

April 21, 1989

Afinitor Delayed Progression Compared To Tamoxifen Alone In Randomized Phase II Study

December 31, 2010

FDA Approves Manufacturer Of IVAX Paclitaxel Ingredient.

June 29, 2001

In Brief: CT Scanning Reduced Morbidity, Mortality, Helps Deliver Optimal Treatment, Consensus Panel Says

November 27, 1981